 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
21 September 1999 | Volume 131 Issue 6 | Pages 463-466
The Heart and Estrogen/progestin Replacement Study (HERS) found no overall effect of 4.1 years of therapy with estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. However, within the overall null effect, a 50% increase in cardiovascular events was seen in the first year, followed by fewer events after 2 years of treatment in the hormone therapy group than in the placebo group. Understanding the cause of this pattern of early increase and late reduction in risk is key to interpreting the HERS results and reconciling them with the large number of observational and other studies of the cardiovascular effects of estrogen. There are two possibilities. One is that the HERS regimen of estrogen plus progestin has no effect on risk for heart disease, and the pattern of changing risk over time is simply the result of chance or confounding. The other is that the pattern of early increase and late reduction in risk is due to real but opposing effects of this regimen. Several lines of evidence support each possibility. Attrition of a susceptible cohort of women uniquely at risk for a cardiovascular complication from hormone therapy coupled with a gradually progressive beneficial effect due to lipid lowering and other factors is a promising potential explanation. The HERS results remind us of the need for clinical trials to evaluate both the benefits and risks of new therapies. They also illustrate how much more we need to know about the cardiovascular effects of hormone replacement therapy.
Author and Article Information
From Wake Forest University School of Medicine, Winston-Salem, North Carolina.
Disclosure: Dr. Herrington is a member of the HERS Executive Committee and has received research support from Wyeth-Ayerst Research, sponsor of the HERS trial.
Requests for Reprints: David M. Herrington, MD, MHS, Department of Internal Medicine/Cardiology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1045; e-mail, dherring{at}wfubmc.edu. PERSPECTIVE
The HERS Trial Results: Paradigms Lost?
This article has been cited by other articles:
|
|
 |
|
  A. Lopez-Ruiz, J. Sartori-Valinotti, L. L. Yanes, R. Iliescu, and J. F. Reckelhoff Sex differences in control of blood pressure: role of oxidative stress in hypertension in females Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H466 - H474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Li, L. Kuo, and J. N. Stallone Estrogen potentiates constrictor prostanoid function in female rat aorta by upregulation of cyclooxygenase-2 and thromboxane pathway expression Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2444 - H2455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. H. Huxley Sex and the cardiovascular system: the intriguing tale of how women and men regulate cardiovascular function differently Advan Physiol Educ, March 1, 2007; 31(1): 17 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gomberg-Maitland, N. K. Wenger, J. Feyzi, M. Lengyel, A. S. Volgman, P. Petersen, L. Frison, and J. L. Halperin Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials Eur. Heart J., August 2, 2006; 27(16): 1947 - 1953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Li and J. N. Stallone Estrogen potentiates vasopressin-induced contraction of female rat aorta by enhancing cyclooxygenase-2 and thromboxane function Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1542 - H1550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Reckelhoff Sex Steroids, Cardiovascular Disease, and Hypertension: Unanswered Questions and Some Speculations Hypertension, February 1, 2005; 45(2): 170 - 174. [Full Text] [PDF]
|
|
|
|
|
|
L. A. Fortepiani, H. Zhang, L. Racusen, L. J. Roberts II, and J. F. Reckelhoff Characterization of an Animal Model of Postmenopausal Hypertension in Spontaneously Hypertensive Rats Hypertension, March 1, 2003; 41(3): 640 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Lehtimaki, P. Dastidar, H. Jokela, T. Koivula, S. Lehtinen, C. Ehnholm, and R. Punnonen Effect of Long-Term Hormone Replacement Therapy on Atherosclerosis Progression in Postmenopausal Women Relates to Functional Apolipoprotein E Genotype J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4147 - 4153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Braunstein, D. W. Kershner, P. Bray, G. Gerstenblith, S. P. Schulman, W. S. Post, and R. S. Blumenthal Interaction of Hemostatic Genetics With Hormone Therapy : New Insights To Explain Arterial Thrombosis in Postmenopausal Women Chest, March 1, 2002; 121(3): 906 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Barrett-Connor, D. Grady, A. Sashegyi, P. W. Anderson, D. A. Cox, K. Hoszowski, P. Rautaharju, K. D. Harper, and for the MORE Investigators Raloxifene and Cardiovascular Events in Osteoporotic Postmenopausal Women: Four-Year Results From the MORE (Multiple Outcomes of Raloxifene Evaluation) Randomized Trial JAMA, February 20, 2002; 287(7): 847 - 857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. McDONNELL, C.-Y. CHANG, and J. D. NORRIS Capitalizing on the Complexities of Estrogen Receptor Pharmacology in the Quest for the Perfect SERM Ann. N.Y. Acad. Sci., December 1, 2001; 949(1): 16 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Heckbert, R. C. Kaplan, N. S. Weiss, B. M. Psaty, D. Lin, C. D. Furberg, J. R. Starr, G. D. Anderson, and A. Z. LaCroix Risk of Recurrent Coronary Events in Relation to Use and Recent Initiation of Postmenopausal Hormone Therapy Arch Intern Med, July 23, 2001; 161(14): 1709 - 1713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Grodstein, J. E. Manson, and M. J. Stampfer Postmenopausal Hormone Use and Secondary Prevention of Coronary Events in the Nurses' Health Study: A Prospective, Observational Study Ann Intern Med, July 3, 2001; 135(1): 1 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Reckelhoff Gender Differences in the Regulation of Blood Pressure Hypertension, May 1, 2001; 37(5): 1199 - 1208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Angerer, S. Stork, W. Kothny, P. Schmitt, and C. von Schacky Effect of Oral Postmenopausal Hormone Replacement on Progression of Atherosclerosis : A Randomized, Controlled Trial Arterioscler. Thromb. Vasc. Biol., February 1, 2001; 21(2): 262 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Blakely The Heart and Estrogen/Progestin Replacement Study Revisited: Hormone Replacement Therapy Produced Net Harm, Consistent With the Observational Data Arch Intern Med, October 23, 2000; 160(19): 2897 - 2900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. ROSTAND Coronary Heart Disease in Chronic Renal Insufficiency: Some Management Considerations J. Am. Soc. Nephrol., October 1, 2000; 11(10): 1948 - 1956. [Full Text]
|
|
|
|
 |
|
 D. M. Herrington, D. M. Reboussin, K. B. Brosnihan, P. C. Sharp, S. A. Shumaker, T. E. Snyder, C. D. Furberg, G. J. Kowalchuk, T. D. Stuckey, W. J. Rogers, et al. Effects of Estrogen Replacement on the Progression of Coronary-Artery Atherosclerosis N. Engl. J. Med., August 24, 2000; 343(8): 522 - 529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Reis, R. Holubkov, J. B. Young, B. G. White, J. N. Cohn, and A. M. Feldman Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies J. Am. Coll. Cardiol., August 1, 2000; 36(2): 529 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. de Jager, T. Pelzer, S. Muller-Botz, A. Imam, J. Muck, and L. Neyses Mechanisms of Estrogen Receptor Action in the Myocardium. RAPID GENE ACTIVATION VIA THE ERK1/2 PATHWAY AND SERUM RESPONSE ELEMENTS J. Biol. Chem., July 20, 2001; 276(30): 27873 - 27880. [Abstract] [Full Text] [PDF]
|
|
Article
